Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [bulk RNA-seq]

ABSTRACT: High tumor mutational burden (TMB) is a predictive biomarker for the responsiveness of cancer to immune checkpoint inhibitor therapy that indicates whether immune cells can sufficiently recognize cancer cells as non-self. However, about 30% of all cancers from The Cancer Genome Atlas are classified as immune-desert tumors lacking T cell infiltration despite high TMB. Since the underlying mechanism of these immune-desert tumors has yet to be unraveled, there is a pressing need to transform such immune-desert tumors into immune-inflamed tumors and thereby enhance their responsiveness to anti-PD1 therapy. Here, we present a systems framework for identifying immuno-oncotargets, based on analysis of gene regulatory networks, and validating the effect of these targets in transforming immune-desert into immune-inflamed tumors. In particular, we identify DEAD-box helicases 54 (DDX54) as a master regulator of immune escape in immune-desert lung cancer with high TMB, and show that knockdown of DDX54 can increase immune cell infiltration and lead to improved sensitivity to anti-PD1 therapy.

ORGANISM(S): Mus musculus

PROVIDER: GSE285342 | GEO | 2025/03/19

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [miRNA-Seq]

Project description:High tumor mutational burden (TMB) is a predictive biomarker for the responsiveness of cancer to immune checkpoint inhibitor therapy that indicates whether immune cells can sufficiently recognize cancer cells as non-self. However, about 30% of all cancers from The Cancer Genome Atlas are classified as immune-desert tumors lacking T cell infiltration despite high TMB. Since the underlying mechanism of these immune-desert tumors has yet to be unraveled, there is a pressing need to transform such immune-desert tumors into immune-inflamed tumors and thereby enhance their responsiveness to anti-PD1 therapy. Here, we present a systems framework for identifying immuno-oncotargets, based on analysis of gene regulatory networks, and validating the effect of these targets in transforming immune-desert into immune-inflamed tumors. In particular, we identify DEAD-box helicases 54 (DDX54) as a master regulator of immune escape in immune-desert lung cancer with high TMB, and show that knockdown of DDX54 can increase immune cell infiltration and lead to improved sensitivity to anti-PD1 therapy.

2025-03-19 | GSE289119 | GEO

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [Xenium]

2025-03-19 | GSE285341 | GEO

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden

2025-03-19 | GSE268555 | GEO

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden

Project description:DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden

| PRJNA1117802 | ENA

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [Xenium]

Project description:DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [Xenium]

| PRJNA1203202 | ENA

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [miRNA-Seq]

Project description:DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [miRNA-Seq]

| PRJNA1221574 | ENA

DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [bulk RNA-seq]

Project description:DDX54 inhibition enhances anti-PD1 therapy in immune-desert lung tumors with high tumor mutational burden [bulk RNA-seq]

| PRJNA1203199 | ENA

In situ tumor arrays reveal early environmental control of cancer immunity [Whole Exome Sequencing]

Project description:We use a laser to implant tumor cells in a regular pattern on the ears of the animal. When GFP expressing tumor cells are implanted in a CD4-Cre Tdtomato mouse we can perform live imaging of red T Cells trafficking in and out of each micro-tumor of the array. Thanks to live imaging we were able to classified each of the implanted tumors as: 1-Rejected tumors (no GFP+ tumor cells anymore but lots of immune cells), 2- Inflamed tumors (GFP+ tumors infiltrated with lots of immune cells), 3-Excluded Tumors (GFP+ tumors with immune cells segregated around the tumor area) or Desert tumors (GFP+ tumor cells without any immune cells). As these tumors are implanted just under the epidermis, we were able to biopsy them out and pool them by categories (Rejected, Inflamed, Excluded and Desert). We froze down biopsies of pooled tumors for each category (Rejected, Inflamed, Excluded and Desert) and extracted DNA. We wish to characterize these 4 kinds of tumors (DNA seq) to evaluate how much tumors grown in the same animals from a clonal KPP tumor cell line differ from each other in terms of mutation load.

2023-02-17 | GSE222540 | GEO

Noncanonical role of NCOR1 as a facilitator of DNA mismatch repair and its deficiency sensitizes cancers to immune checkpoint blockade therapy [scRNA-seq]

Project description:Tumor genomic heterogeneity significantly influences the efficacy of immune checkpoint blockade (ICB) therapy. To elucidate the underlying mechanisms, we pioneered the development of an ICB response score (IRS) based on machine learning analysis of microenvironmental features. Through a pan-cancer genomic screening, we identified the nuclear receptor corepressor NCOR1 as a key regulator, the tumors with genomic deficiency of which display a tumor infiltrating lymphocyte (TIL)-inflamed microenvironment. Genetic ablation of Ncor1 delays the tumorigenesis and metastasis in syngeneic and spontaneous tumor models in immunocompetent mice. Mechanistically, NCOR1 guards DNA mismatch repair by directly interacting with MSH2 and recruiting MutSa to chromatin for mismatch recognition, independent of its transcriptional regulatory activity coupling with histone deacetylase. Ncor1 depletion in hepatocellular carcinoma and melanoma cells promotes tumor immunogenicity by increasing tumor mutation burden (TMB), neoantigen load, and TIL infiltration and activation, thereby enhancing anti-PD-1 therapy efficacy. Our findings reveal that NCOR1 loss represents a novel mechanism underlying TMB-high tumors with intact MMR components, broadening the application of ICB.

2025-03-03 | GSE290694 | GEO

Noncanonical role of NCOR1 as a facilitator of DNA mismatch repair and its deficiency sensitizes cancers to immune checkpoint blockade therapy

2025-03-01 | GSE290464 | GEO